Sanofi India Ltd vs Vista Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3402 as of 05 May 15:30 . The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 .The P/E Ratio of Vista Pharmaceuticals Ltd is 0 as of December 2023 . The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 .The Market Cap of Vista Pharmaceuticals Ltd is ₹ 0 crore as of December 2023 . The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 .The Revenue of Vista Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 .The EBITDA of Vista Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 .The Net Profit of Vista Pharmaceuticals Ltd is ₹ 0 crore as of Jun '24 . The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Vista Pharmaceuticals Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Limited was incorporated on January 25,1991 with the Registrar of Companies, Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991.
The Company is engaged in the formulation of pharmaceutical products.
It offers a range of products mainly into the therapeutic areas of gastrointestinal, pain management and anti-infection, catering to common ailments.
This division is a primary contributor to the domestic sales of Torrent Pharmaceuticals Ltd., based in Hyderabad, India. The Company was in process of setting up a 100% EOU for manufacture of drug formulations with an installed capacity of 400 million tablets & 200 million capsules per annum.
Apart from these, the Company offers over the counter & prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories.

FAQs for the comparison of Sanofi India Ltd and Vista Pharmaceuticals Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Vista Pharmaceuticals Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Vista Pharmaceuticals Ltd is 49 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Vista Pharmaceuticals Ltd?

The stock performance of Sanofi India Ltd and Vista Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Vista Pharmaceuticals Ltd?

As of May 5, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Vista Pharmaceuticals Ltd stock price is INR ₹7.98.

How do dividend payouts of Sanofi India Ltd and Vista Pharmaceuticals Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Vista Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.